Antitumor activity of dextran derivatives immobilizing platinum complex (II).

Abstract

The in vivo antitumor activity and toxicity of a newly synthesized polymeric prodrug of cisplatin was investigated and also compared with plain cisplatin. The prodrug included a dicarboxymethyl-dextran conjugate of cisplatin (DCM-Dex/CDDP). DCM-Dex/CDDP was i.v. injected in mice bearing s.c. Colon 26 mouse colon cancer cells. The tissue distribution of platinum was thereafter determined by flameless atomic absorption spectrophotometry. The platinic concentration of the organs showed a high rate of retention at 24 h after injection in the DCM-Dex/CDDP-treated mice. No biochemical or hematologically adverse effects were observed. In addition, DCM-Dex/CDDP showed a significantly higher antitumor activity than cisplatin alone. These results indicate that DCM-Dex/CDDP may therefore be a potentially effective cancer chemotherapy.

• Authors: K Ichinose, N Tomiyama, M Nakashima, Y Ohya, M Ichikawa, T Ouchi, T Kanematsu
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 11 Issue 1 Pg. 33-8 (Jan 2000) ISSN: 0959-4973 [Print] England
• PMID: 10757561 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• DCM-Dex-CDDP
• Dextrans
• Prodrugs
• Cisplatin

Topics

• Animals
• Antineoplastic Agents (pharmacokinetics, pharmacology)
• Cisplatin (pharmacokinetics, pharmacology)
• Dextrans (pharmacology)
• Disease Models, Animal
• Male
• Mice
• Mice, Inbred BALB C
• Neoplasm Transplantation
• Neoplasms, Experimental (drug therapy, metabolism)
• Prodrugs (pharmacokinetics, pharmacology)
• Tissue Distribution
• Transplantation, Heterologous